Reliability of A Dried Urine Test for Comprehensive Assessment of Urine Hormones and Metabolites

Mark Newman (mnewman@dutchtest.com)
Precision Analytical, Inc.

Desmond Curran
Precision Analytical, Inc.

Research Article

Keywords: dried urine testing, GC-MS/MS, LC-MS/MS, reproductive hormones, estrogen, testosterone, androgens, organic acids

DOI: https://doi.org/10.21203/rs.3.rs-122134/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Mass spectrometry allows for analysis of multiple hormone and organic acid metabolites from small urine volumes; however, to assess the full extent of daily hormone production, 24-hour urine collections are usually required. The aims of this study were, first, to confirm that mass spectrometric analysis of an array of hormones and organic acids would yield similar results in both liquid and dried urine, and, second, to determine if collection of four dried spot urine samples could be substituted for a 24-hour collection when measuring reproductive hormones.

Methods

Two study populations were included in this prospective observational study. Twenty individuals collected both a spot liquid urine and dried urine on filter paper to analyze eight organic acids. A second group of 26 individuals collected both a 24-hour urine and four dried spot urines during waking hours throughout the same day for evaluation of 17 reproductive hormones and metabolites; data from 18 of these individuals were available to compare liquid versus dried urine results. Dried urine was extracted, hydrolyzed, and derivatized before analysis by mass spectrometry; all analytes from dried urine were normalized to urine creatinine.

Results

Reproductive hormone results from dried and liquid urine were in excellent agreement with intraclass correlation coefficients (ICCs) greater than 0.90; comparison of dried to liquid urine for organic acids showed good to excellent agreement (ICC range: 0.75 to 0.99). Comparison between the 4-spot urine collection and 24-hour urine collection methods showed excellent agreement (ICC>0.9) for 14 of the 17 urine metabolites and good agreement for the others (ICC 0.78 to 0.85) with no systematic differences between the two methods of collection.

Conclusions

The burden of urine collection can be reduced using collection of four spot dried urines on filter paper without compromising comparability with hormone results from a 24-hour urine collection. A large number of urine analytes can be assessed from the dried urine with similar results to those from liquid urine. Given the ease of sample handling, this 4-spot dried urine assay would be useful for both clinical assessment of patients and for large epidemiologic studies.

Introduction

Analysis of an array of hormones or metabolites may be useful for the clinician faced with a patient with a multitude of nonspecific symptoms that lead to a large differential of diagnoses, for screening of multiple diseases at once, for a patient on hormonal replacement therapy, or for any patient where a
complete picture of production and metabolism of a hormonal pathway is required. Measurement of steroid hormones in urine can be an essential component to the diagnosis of hormone-related disorders. Some patients may require sampling over multiple days to determine monthly variations or effects of change in treatment. For hormones with known circadian or pulsatile fluctuations, a representation of the entire day is essential; however, collection and storage of a 24-h urine can be cumbersome for patients.

Mass spectrometry technology, both liquid chromatography tandem mass spectrometry (LC-MS/MS) for water-soluble compounds and gas chromatography tandem mass spectrometry (GC-MS/MS) for non-polar compounds, is now routinely used to measure arrays of steroid hormones and organic acids because of its high assay sensitivity, accuracy with small volumes, and ability to evaluate multiple analytes at the same time. This methodology allows for a complete profile of urine reproductive hormonal metabolites and multiple organic acids with high resolution of closely related structures.

Collection of urine on filter paper, which can then be dried and stored at room temperature until received by the laboratory, offers a significant advance in patient convenience and may improve patient adherence. If multiple samples are collected throughout the day, there is potential to capture both the diurnal variation of hormones along with the full range of daily hormonal production. Dried urine has already been shown to lead to equivalent measures as liquid urine in our hands for cortisol, cortisone, and the cortisol metabolites, a-tetrahydrocortisol, b-tetrahydrocortisol, and tetrahydrocortisone as well as for estrone, estradiol, a-pregnanediol, and b-pregnanediol. Others have found similar results between liquid and dried urine with organic acids. The urinary analytes in this study included female and male reproductive hormones, 6-hydroxymelatonin sulfate, and a number of organic acids, which have a multitude of uses (Table 1). Inclusion of multiple metabolites from the estrogen and androgen pathways allows for a complete picture of estrogen and testosterone production and metabolism.

The primary goal of this study was to confirm that measurement of the urinary profile of reproductive hormones, 6-hydroxymelatonin sulfate, and an array of organic acids extracted from dried urine collected on filter paper as analyzed by tandem mass spectrometry would provide results in agreement with measurements from liquid urine. The secondary aim was to demonstrate that measurement of reproductive hormones in a collection of four dried urine samples over a 15-hour span throughout the day would accurately reflect the measurements of these hormones in a 24-h urine collection.
| Variable         | Pathway                                      | Examples of Clinical Relevance                                                                                                                                 |
|------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Estrone          | Estrogen; estradiol metabolite               | Monitoring of hormonal replacement therapy; assessment of ovarian function or precocious puberty; evaluation of dietary effects<sup>19–23</sup>          |
| Estradiol        | Primary active estrogen                      | Investigation of amenorrhea; assessment of precocious puberty; monitoring of hormonal replacement therapy; evaluation of dietary effects<sup>19,23−26</sup> |
| Estriol          | Estrogen; estrogen metabolite via 16α-hydroxyestrone | Monitoring of hormonal replacement therapy; evaluation of polycystic ovarian syndrome (PCOS); evaluation of dietary effects<sup>19,23,27</sup> |
| 2-hydroxyestrone | Estrogen metabolite via estrone              | Estrogen receptor antagonist; antiproliferative; relative to other metabolites, may indicate health risks<sup>24,25,28,29</sup>                             |
| 2-hydroxyestradiol | Estrogen metabolite via 2-hydroxyestrone   | Antiproliferative; relative to other metabolites, may indicate health risks; potential placental antioxidant<sup>30</sup>                                   |
| 4-hydroxyestrone | Estrogen metabolite via estrone              | Estrogen receptor agonist; relative to other metabolites, may indicate health risks; may be proangiogenic<sup>29</sup>                                    |
| 16-hydroxyestrone | Estrogen metabolite via estrone              | Estrogen receptor agonist; proliferative; relative to other metabolites, may indicate health risks; 2/16OHE1 ratio may be a marker of estrogen related cancer risk; together with estriol indicates activity of 16-hydroxylation pathway<sup>24,25,28,29</sup> |
| 2-methoxyestrone | Estrogen metabolite via 2-hydroxyestrone    | May be anti-angiogenic; together with 2-hydroxyestrone and 2-hydroxyestradiol indicates activity of 2-hydroxylation pathway<sup>31,32</sup>             |
| Testosterone     | Primary active androgen                      | Evaluation of male hypogonadism and infertility; monitoring of hormone therapy; anabolic to muscle and bone; evaluation of PCOS<sup>18,19,33−35</sup> |
| Epitestosterone  | Inactive epimer of testosterone              | Evaluation of exogenous testosterone use; weak androgen antagonist<sup>18,35</sup>                                                                              |
| 5α-Dihydrotestosterone | Active form of testosterone in tissues     | Potent androgen; evaluation of hirsutism; evaluation of male infertility, hypogonadism, and low libido<sup>18,36</sup>                        |

<sup>5-HIAA = 5-hydroxyindoleacetic acid; DHEA = dehydroepiandrosterone</sup>
| Variable         | Pathway                                                                 | Examples of Clinical Relevance                                                                 |
|------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Androsterone     | Metabolite of testosterone via 5αDHT                                   | Weak androgenic activity; neurosteroid; primary androgen metabolite in urine; evaluation of male infertility, hypogonadism, low libido, and hormone therapy; evaluation of PCOS\textsuperscript{18,37} |
|                  |                                                                         | **Etiocholanolone** 5β epimer of androsterone                                                  | Primary androgen metabolite in urine; inhibitory neurosteroid; evaluation of male infertility, hypogonadism, low libido, and hormone therapy; evaluation of PCOS\textsuperscript{18,37} |
| 5a-Androstanediol| Metabolite of testosterone and 5αDHT                                   | Weak androgenic and estrogenic properties; inhibitory neurosteroid; involved in prostate growth; evaluation of male infertility, hypogonadism, and low libido; evaluation of PCOS\textsuperscript{18,27} |
| 5b-Androstanediol| Metabolite of testosterone and 5αDHT, β epimer of 5α-androstanediol    | Has estrogen agonist properties; evaluation of male infertility, hypogonadism, and low libido; evaluation of PCOS\textsuperscript{18,27} |
| DHEA             | Major metabolite in urine is DHEAS                                      | Weak androgen produced by adrenal glands and brain; neurosteroid; implicated in neurocognitive declines and low libido; assessment of hirsutism and age-related changes in women; assessment of subclinical hypercortisolism\textsuperscript{36,38} |
| 6-Hydroxymelatonin sulfate | Metabolite of melatonin                                              | Representative of melatonin which is involved in the regulation of the sleep-wake cycle and promotes sleep; neuroprotective; evaluation of insomnia, fatigue, and infertility\textsuperscript{39,40} |
| Methylmalonic Acid | Intermediate in the propionate pathway                                | Increased in thiamine (B12) deficiency\textsuperscript{41}                                      |
| Homovanillic Acid | Metabolite of dopamine                                                | Elevated in cases of neuroblastoma; marker of metabolic stress in patients with psychiatric and neurologic diseases\textsuperscript{42} |
| Vanillylmandelic Acid | Metabolite of norepinephrine                                         | Elevated in cases of neuroblastoma or pheochromocytoma\textsuperscript{42,43}                     |
| Kynurenic Acid   | Metabolite of tryptophan                                              | Part of the kynureninase pathway; increased in pyridoxine (B6) deficiency\textsuperscript{44–47} |
| Xanthurenic Acid | Metabolite of tryptophan                                              | Part of the kynureninase pathway; increased in pyridoxine (B6) deficiency; possible measure of oxidative stress\textsuperscript{46–48} |

5-HIAA = 5-hydroxyindoleacetic acid; DHEA = dehydroepiandrosterone
| Variable       | Pathway                        | Examples of Clinical Relevance                                                                                                                                 |
|---------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5-HIAA        | Metabolite of tryptophan      | End product of serotonin metabolism; elevated in carcinoid syndrome; reduced in patients with major depressive disorder\(^{42,49,50}\)                                     |
| Pyroglutamic Acid | Intermediate in glutathione metabolism | Increased in glutathione (an antioxidant) deficiency, as can occur with excess acetaminophen use\(^{51,52}\)                                                 |
| b-Hydroxyisovaleric Acid | Metabolite of leucine         | Increased in biotin (B7) deficiency and in smokers\(^{53,54}\)                                                                                                   |

5-HIAA = 5-hydroxyindoleacetic acid; DHEA = dehydroepiandrosterone

**Methods**

**Study populations**

A prospective observational study of urine collected from a population of healthy adult volunteers who agreed to participate in validation of urine analyses was conducted. This first study population included 26 individuals who provided data on hormonal measures (cortisol and cortisol metabolites, reproductive hormones, and 6-hydroxymelatoninsulfate) to compare samples from the 4-spot urine collection method to a 24-hour urine collection. A subset of these individuals (n = 18) had data available to compare measures from dried versus liquid urine. As cortisol and cortisol metabolites\(^{15}\) and a and b-pregnandiol\(^{12}\) were validated in previous analyses, only the following hormones were included in this analysis: estrone (E1), estradiol (E2), estriol (E3), 2-hydroxyestrone (2OHE1), 2-hydroxyestradiol (2OHE2), 4-hydroxyestrone (4OHE1), 16-hydroxyestrone (16OHE1), 2-methoxyestrone (2-methoxyE1), testosterone (T), epitestosterone (EpiT), 5a-dihydrotestosterone (DHT), androsterone, etiocholanolone, 5a-androstenediol, 5b-androstanediol, dehydroepiandrosterone (DHEA), and 6-hydroxymelatoninsulfate. The data were collected between February and November of 2015 and informed consent was obtained from all participants.

The second analysis included 20 individuals whose deidentified data was pulled from the larger databank of 144,561 laboratory visits. Each of these samples included a single first-morning urine collection to compare results of dried versus liquid urine for the following organic acids: homovanillic acid (HVA), vanillylmandelic acid (VMA), kynurenic acid, xanthurenic acid, methymalonic acid (MMA), pyroglutamic acid, 5-hydroxyindoleacetic acid (5-HIAA), and b-hydroxyisovaleric (Hiv) acid. All data reports were deidentified during extraction so the IRB determined that written informed consent could be waived for this study population. Both studies (Clinical Trials ID: NCT04305093) were approved by the National University of Natural Medicine Institutional Review Board.

All volunteers in both study populations reported no medical problems and were not pregnant. Individuals were not excluded based on current or recent use of any hormonal medications, as the goal was only to
compare measurement values for differing methodologies. Eighty percent of women in the first study population and all women in the second study population were premenopausal.

Sample Collection

The 4-spot method involves urine samples collected at home at four times during the day: 1) the first urine of the day, 2) two hours after awakening, 3) in the afternoon (approximately 4 PM), and 4) before bed (10PM). Participants collected samples by completely saturating 2 × 3 inches of filter paper (Whatman Body Fluid Collection Paper) with urine. The paper was left exposed at room temperature for 24 hours to dry. The stability of analytes in dried urine at room temperature for as long as 84 days has previously been demonstrated by this laboratory\textsuperscript{12}. Dried samples were stored at -80°C until analyzed. Reproductive hormones were assessed in all four samples collected, while only the first morning sample was used for 6-hydroxymelatoninsulfate and the organic acid tests.

During the same day, all liquid urine samples for the 24-hour collection were added to a low-density polyethylene plastic container (ES Robbins, USA) container with approximately 1 g of boric acid and kept refrigerated for the duration of the collection. The four dried urine samples removed a total of about 8 mL of urine from the 24-hour collection. This was considered negligible and was not accounted for. The total volume of urine from 24-hour collections was measured, and an aliquot was frozen and stored at -80°C until tested.

Urine Reproductive Hormone Analysis

The urinary steroid hormones were analyzed using proprietary in-house CLIA (Clinical Laboratory Improvement Amendments) approved assays on the Agilent 7890/7000B GC-MS/MS (Agilent Technologies, Santa Clara, CA, USA). A 600 ul aliquot of liquid urine was taken from the sample collection and the equivalent of approximately 600 ul of urine was extracted from the filter paper using 2 mL of 100 mM ammonium acetate adjusted to a pH of 5.9. These aliquots of the conjugated hormones were transferred to a C18 solid phase extraction (SPE) column (UCT LLC, Briston, PA, USA), eluted using methanol, and the eluate was dried under nitrogen at 40 °C.

The conjugated hormones were then hydrolyzed from their glucuronide and sulfate forms to free forms using enzymes from \textit{Helix pomatia} (Sigma-Aldrich, St. Louis, MO, USA) in acetate buffer (55 °C, 90 minutes). The enzymatic reaction was quenched with sodium hydroxide and the hormones extracted with ethyl acetate. The ethyl acetate extracts were dried under nitrogen at 40 °C. The analytes were derivatized using a mixture of 100 ul acetonitrile (ACN) and 50 ul bis(trimethylsilyl)trifluoroacetamide (Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes at 70 °C. Internal standards (Steraloids, Newport, RI, USA) were added prior to ethyl acetate extraction, and the percentage recovery from all assays was greater than 90%. Derivatized extract (1.6 ul) was injected into the GC-MS/MS. Samples and controls were analyzed along with a standard curve spanning the expected range of concentrations. Instrument conditions for the oven...
were an initial temperature of 130 °C increasing to 200 °C at 25 °C /min, then to 230 °C at 4.3 °C /min, and finally to 290 °C at 25 °C /min. Multiple reaction monitoring transitions for ion mass > ion product of fragmentation were 342.1 > 257.1 for E1, 416.2 > 285.1 for E2, 504.3 > 296.3 for E3, 430.2 > 345.0 for 2OHE1, 462.2.2 > 195.2 for 2OHE2, 430.2 > 354.0 for 4OHE1, 430.2 > 286.1 for 16OHE1, 372.2-342.1 for 2-methoxyE1, 360.2 > 174.1 for T, 360.2 > 174.1 for EpiT, 347.2 > 296.3 for E3, 430.2 > 354.0 for 4OHE1, 430.2 > 286.1 for 16OHE1, 372.2-342.1 for 2OHE1, 462.2.2 > 195.2 for 2OHE2, 430.2 > 354.0 for 4OHE1, 430.2 > 286.1 for 16OHE1, 372.2-342.1 for 2-methoxyE1, 360.2 > 174.1 for T, 360.2 > 174.1 for EpiT, 347.2 > 271.2 for DHT, 347.2 > 271.2 for androsterone, 347.2 > 253 for etiocholanolone, 421.2 > 331.2 for 5α-androstanediol, 241.2 > 185.2 for 5β-androstanediol, and 303.7 > 199.1 for DHEA.

Creatinine was measured using a conventional colorimetric (Jaffe) method, after initial extraction from the filter paper. The average inter-assay coefficient of variation was 6.7% for creatinine. In addition to expressing the measures per mg of creatinine to correct for variations in filter paper saturation and hydration status, a secondary equation was applied to reduce bias related to the effects of age, sex, weight, and height on creatinine excretion.

**Urine 6-hydroxymelatoninsulfate And Organic Acid Analysis**

The hydrophilic analytes were assessed by LC-MS/MS using proprietary in-house CLIA approved assays. For the 6-hydroxymelatoninsulfate assay, a 30 ul aliquot was taken from the methanol elution of both the liquid urine collection and the waking sample dried urine collected on filter paper. This extract was then reconstituted in 130 ul of deionized water. For the organic acids, a 100 ul aliquot of liquid urine was taken and an equivalent amount was extracted from the waking sample dried urine filter paper using 250 ul of water with the addition of 50 ul 100 mM ammonium acetate (Sigma-Aldrich, St. Louis, MO, USA) adjusted to a pH of 5.9 and 2% formic acid.

For 6-hydroxymelatoninsulfate, 20 ul was injected into an ultra-performance liquid chromatography (UPLC) (Waters Corporation, Milford, MA, USA) column with a Waters™ tandem quadrupole mass spectrometer detector (TQD). The sample was eluted from a 1.8u 2.1 × 50 mm pentfluorophenyl (PFP) column (Agilent Technologies, Santa Clara, CA, USA) using a gradient of 95% 0.001% formic acid in 5% ACN to 45% 0.001% formic acid in 55% ACN. For the organic acids, 5 ul was injected into the Waters™ UPLC column with TQD. These analytes were eluted from a 1.6 um 2.1 × 50 mm Luna Omega PS C18 column (Phenomenex, Torrance, CA, USA) using a gradient 99.9% 0.2% formic acid in 0.1% ACN to 73% 0.2% formic acid in 27% ACN. Multiple reaction monitoring transitions for ion mass > ion product of fragmentation were 372.5 > 176.2 for 6-hydroxymelatoninsulfate, 331.5 > 179.2 for d4-6-hydroxymelatoninsulfate, 183.0 > 137.0 for HVA, 185.0 > 139.0 for d2-HVA, 197.0 > 138.0 for VMA, 199.8 > 140.9 for d3-VMA, 190.0 > 144.0 for kynurenic acid, 192.0 > 149.0 for d5-kynurenic acid, 206.0 > 160.0 for xanthurenic acid, 210.0 > 164.0 for d3-xanthurenic acid, 117.0 > 73.0 for MMA, 120.0 > 76.0 for d2-MMA, 130.0 > 84.0 for pyroglutamic acid, 135.0 > 89.0 for d5-pyroglutamic acid, and 192.0 > 146.0 for 5-HIAA. The same creatinine corrections of the measures used for the reproductive hormones were also used for 6-hydroxymelatoninsulfate and the organic acids.
Statistical Methods

A sample size of 18 individuals provides a power of greater than 80% to detect an intraclass correlation coefficient (ICC) of at least 0.6 with an alpha of 0.05\(^5\). The statistical analyses were performed using SAS/STAT® software, Version 9.3 (SAS Institute Inc., Cary, NC, USA) and generated 2-sided p-values.

Variables are described as means ± standard deviation if normally distributed and median (interquartile range (IQR)) if the distribution was skewed. Student’s t-test (for normally distributed variables) or the Wilcoxon rank-sum test (for skewed variables) were used to determine differences between men and women. Spearman correlation coefficients (\(\rho\)) were used to determine interclass associations between variables.

Consistency between liquid versus dried urine measures and 4-spot versus 24-h collection methodology was assessed using intraclass correlation coefficients (ICC). ICCs, which range from 0 to 1 with proximity to 1 indicating better agreement, assess for agreement of a measure between two differing methodologies within individuals\(^5\). Skewed variables were log transformed to approximate a normal distribution prior to assessing ICCs. As 4-spot (ng/mg-Cr) and 24-h (ug/d) measures were expressed in differing units, sex-specific Z-scores ([individual measurement-mean]/standard deviation) were created to standardize the measures and allow for direct comparison. Comparisons of differences between measures within an individual were assessed using signed-rank tests (for skewed variables) or paired t-tests (for normally distributed variables). Because the hypotheses of this paper were intrinsically correlated, no adjustments were made for multiple comparisons.

Results

Study populations

Characteristics of the first study population (n = 26) are shown in Table 2. All of these individuals (58% female; 100% Caucasian) had data available for comparison of 4-spot versus 24-h urine samples for male and female reproductive hormones. A subset (10 female, 8 male) also had measurements to compare liquid versus dried urine samples for both the reproductive hormones and 6-hydroxymelatonin sulfate. Characteristics of the second study population (n = 20; 75% female; 80% Caucasian / 10% Hispanic / 10% Asian-Pacific Islander), data from whom were used to compare a single first morning collection of liquid versus dried urine samples for the organic acid tests, are provided in Table 3.
Table 2
Age and 24-h measures of reproductive hormones and 6-hydroxymelatoninsulfate of the first study population.

| Variable                        | All          | Female (n = 15) | Male (n = 11) |
|---------------------------------|--------------|-----------------|---------------|
| Age (years)                     | 36.8 ± 14.5  | 33.7 ± 7.8      | 37.8 ± 18     |
| Estrone (ug/d)<sup>a</sup>      | 13.69 (6.32, 19.16) | 18.75 (6.83, 23.68) | 7.67 (6.26, 13.68) |
| Estradiol (ug/d)<sup>a</sup>    | 1.73 (0.80, 3.26)  | 3.17 (0.89, 4.19)  | 1.14 (0.70, 1.62)  |
| Estriol (ug/d)<sup>a</sup>      | 6.82 (3.57, 12.80) | 11.64 (6.14, 16.55) | 5.56 (3.45, 6.91)  |
| 2-hydroxyestrone (ug/d)<sup>a</sup> | 3.33 (1.27, 6.24) | 5.82 (0.77, 8.46) | 2.26 (1.27, 4.03) |
| 2-hydroxyestriadiol (ug/d)<sup>a</sup> | 0.25 (0.11, 0.67) | 0.58 (0.06, 0.81) | 0.19 (0.11, 0.26) |
| 4-hydroxyestrone (ug/d)<sup>a</sup> | 0.37 (0.19, 0.75) | 0.67 (0.19, 0.99) | 0.30 (0.16, 0.36) |
| 16-hydroxyestrone (ug/d)<sup>a</sup> | 0.89 (0.42, 1.48) | 1.40 (0.36, 1.58) | 0.49 (0.42, 0.90) |
| 2-methoxyestrone (ug/d)<sup>a</sup> | 2.27 (1.30, 3.80) | 3.56 (1.38, 5.50) | 1.63 (1.05, 2.35) |
| Testosterone (ug/d)<sup>b</sup> | 9.15 (4.97, 51.92) | 5.43 (4.51, 8.01) | 61.40 (42.14, 97.70) |
| Epitestosterone (ug/d)<sup>b</sup> | 7.23 (4.01, 11.23) | 4.44 (1.18, 7.49) | 14.94 (7.99, 16.80) |
| 5a-Dihydrotestosterone (ug/d)<sup>b</sup> | 5.53 (2.72, 11.59) | 2.72 (1.33, 5.46) | 12.60 (9.88, 17.47) |
| Androsterone (ug/d)<sup>a</sup> | 1331.99 (854.41, 1940.29) | 1032.77 (691.70, 1528.59) | 2083.52 (1005.51, 2716.33) |
| Etiocholanolone (ug/d)<sup>a</sup> | 811.74 (463.17, 1045.23) | 568.56 (430.73, 853.81) | 1020.79 (716.22, 1423.92) |
| 5a-Androstanediol (ug/d)<sup>b</sup> | 102.50 (54.83, 197.14) | 58.72 (46.49, 97.50) | 229.01 (143.30, 292.53) |
| 5b-Androstanediol (ug/d)<sup>a</sup> | 35.58 (14.05, 60.75) | 15.83 (9.38, 52.69) | 60.75 (20.69, 122.18) |
| DHEA (ug/d)                      | 166.14 (80.45, 431.61) | 136.42 (80.45, 317.83) | 351.32 (52.69, 732.63) |
| 6-Hydroxymelatonininsulfate (ug/ml) | 7.87 (5.93, 13.85) | 7.48 (5.93, 8.43) | 12.21 (5.11, 20.06) |

Age presented as mean ± SD; hormone data presented as median (IQR) as these data were skewed.

<sup>a</sup> p < 0.05; <sup>b</sup> p < 0.01 for differences between males and females as assessed by the Wilcoxon rank-sum test.

DHEA = dehydroepiandrosterone
Table 3
Age and measures of organic acids from an early morning spot urine collection of the second study population.

| Variable                       | All            | Female (n = 15) | Male (n = 5) |
|--------------------------------|----------------|----------------|--------------|
| Age (years)                    | 34.4 ± 6.6     | 34.5 ± 6.6     | 34.0 ± 7.4   |
| Methylmalonic Acid (ng/mg-Cr)  | 0.18 (0.16, 0.25) | 0.20 (0.16, 0.29) | 0.16 (0.16, 0.18) |
| Homovanillic Acid (ng/mg-Cr)² | 0.52 ± 0.16    | 0.57 ± 0.14    | 0.35 ± 0.05  |
| Vanillylmandelic acid (ng/mg-Cr)| 0.41 ± 0.12    | 0.43 ± 0.12    | 0.36 ± 0.13  |
| Kynurenic Acid (ng/mg-Cr)      | 0.25 ± 0.08    | 0.26 ± 0.08    | 0.21 ± 0.05  |
| Xanthurenic Acid (ng/mg-Cr)    | 0.06 (0.05, 0.07) | 0.06 (0.04, 0.07) | 0.06 (0.05, 0.07) |
| 5-HIAA (ng/mg-Cr)ᵃ             | 0.44 (0.40, 0.55) | 0.47 (0.41, 0.58) | 0.37 (0.36, 0.41) |
| Pyroglutamic Acid (ng/mg-Cr)   | 4.06 ± 0.69    | 4.11 ± 0.78    | 3.90 ± 0.33  |
| b-Hydroxyisovaleric Acid (ng/mg-Cr) | 0.27 ± 0.12    | 0.29 ± 0.13    | 0.21 ± 0.07  |

Data are presented as mean ± SD if normally distributed and median (IQR) if right-skewed.

ᵃ p < 0.05, ᵇ p < 0.01 for differences between males and females as assessed by the Student t-test or Wilcoxon rank-sum test.

5-HIAA = 5-hydroxyindoleacetic acid

**Agreement Between Liquid And Dried Urine Measures**

For the majority of analytes, there was excellent agreement (ICC ≥ 0.90) between the liquid and dried measures (Table 4). The exceptions were VMA (ICC = 0.79) and pyroglutamic acid (ICC = 0.75), which still had good agreement. Similarly, for the majority of analytes, there was no systemic directionality to the difference in the dried urine compared to the liquid urine. However, estrone and estriol were consistently higher when measured in liquid urine, while some of the organic acids – VMA, kynurenic acid, pyroglutamic acid, and b-hydroxyisovaleric acid – were more concentrated in the dried urine sample (Table 4). Representative interclass correlations (Spearman) between the two methods are shown in Fig. 1 (the rest are available in Supplementary Fig. 1).
Table 4
Comparison of liquid versus dried urine analytes (n = 18).

| Variable                | Dried            | Liquid           | Difference [95% CI] | ICC [95% CI] |
|-------------------------|------------------|------------------|---------------------|---------------|
| **Hormones (n = 18)**   |                  |                  |                     |               |
| Estrone (µg/d)          | 10.78 (6.26, 18.73) | 12.78 (7.22, 20.65) | 1.28 [0.09, 2.47]^a | 0.92 [0.80, 0.97] |
| Estradiol (µg/d)        | 1.32 (0.70, 3.26)  | 1.29 (0.74, 3.36)  | 0.09 [-0.01, 0.19]  | 0.96 [0.89, 0.98] |
| Estriol (µg/d)          | 6.82 (3.45, 11.64) | 7.15 (4.76, 14.41) | 0.86 [0.05, 1.67]^a | 0.90 [0.77, 0.96] |
| 2-hydroxyestrone (µg/d) | 2.22 (0.98, 6.24)  | 1.84 (1.17, 6.24)  | -0.01 [-0.18, 0.16] | 0.98 [0.94, 0.99] |
| 2-hydroxyestradiol (µg/d) | 0.18 (0.09, 0.58) | 0.18 (0.08, 0.47) | 0.00 [-0.02, 0.03] | 0.97 [0.92, 0.99] |
| 4-hydroxyestrone (µg/d) | 0.31 (0.16, 0.67)  | 0.40 (0.25, 0.62)  | 0.03 [-0.02, 0.09]  | 0.95 [0.87, 0.98] |
| 16-hydroxyestrone (µg/d) | 0.69 (0.42, 1.48) | 0.61 (0.39, 1.24) | -0.07 [-0.18, 0.05] | 0.95 [0.87, 0.98] |
| 2-methoxyestrone (µg/d) | 1.64 (1.05, 3.56) | 1.70 (1.50, 3.58) | 0.12 [-0.07, 0.30]  | 0.97 [0.94, 0.99] |
| Testosterone (µg/d)     | 7.64 (4.97, 49.46) | 8.42 (5.80, 51.40) | 2.07 [-0.26, 4.40]  | 0.99 [0.98, 1.00] |
| Epitestosterone (µg/d)  | 7.23 (4.01, 11.23) | 8.21 (4.23, 13.98) | 0.51 [-0.06, 1.07]  | 0.99 [0.97, 1.00] |
| 5α-Dihydrotestosterone (µg/d) | 5.53 (2.72, 11.59) | 4.94 (2.68, 10.35) | -0.61 [-1.02, -0.19]^a | 0.99 [0.97, 1.00] |
| Androsterone (µg/d)     | 1331.99 (929.43, 1933.30) | 1237.63 (813.31, 1847.10) | -33.32 [-105.70, 39.67] | 0.99 [0.98, 1.00] |
| Etiocholanolone (µg/d)  | 847.93 (430.73, 1088.18) | 943.49 (414.13, 1161.61) | 19.76 [-13.02, 52.54] | 0.99 [0.98, 1.00] |

For liquid and dried measurements, data presented as mean±SD for normally distributed variables and median (IQR) for skewed variables; the differences were normally distributed and are presented as mean [95% CI].

^ap<0.05; bp<0.0001 for the liquid minus dried difference by paired t-test

5-HIAA = 5-hydroxyindoleacetic acid, Cr = creatinine, DHEA = dehydroepiandrosterone, ICC = intraclass correlation coefficient
| Variable                                      | Dried                          | Liquid                         | Difference                  | ICC [95% CI]    |
|-----------------------------------------------|--------------------------------|--------------------------------|-----------------------------|----------------|
| 5α-Androstanediol (ug/d)                      | 110.09 (57.50, 197.14)         | 119.40 (65.63, 226.93)         | 15.67 [-12.67, 44.01]      | 0.90 [0.76, 0.96] |
| 5β-Androstanediol (ug/d)                      | 35.58 (14.05, 72.42)           | 46.39 (14.72, 65.39)           | -0.54 [-13.93, 12.85]      | 0.88 [0.73, 0.95] |
| DHEA (ug/d)                                   | 131.42 (52.69, 444.35)         | 130.86 (53.27, 457.05)         | 8.65 [-36.66, 53.96]       | 1.00 [0.99, 1.00] |
| 6-Hydroxymelatonin sulfate (ug/d)             | 7.87 (5.93, 14.33)             | 8.26 (5.93, 14.67)             | 0.04 [-1.14, 1.21]         | 0.99 [0.98, 1.00] |

Organic Acids (n = 20)

| Variable                                      | Dried                          | Liquid                         | Difference                  | ICC [95% CI]    |
|-----------------------------------------------|--------------------------------|--------------------------------|-----------------------------|----------------|
| Methylmalonic Acid (ng/mg-Cr)                 | 0.18 (0.15, 0.23)              | 0.18 (0.16, 0.25)              | 0.00 [-0.01, 0.02]          | 0.96 [0.90, 0.98] |
| Homovanillic Acid (ng/mg-Cr)                  | 0.52 ± 0.17                    | 0.52 ± 0.16                    | -0.01 [-0.05, 0.02]         | 0.88 [0.74, 0.95] |
| Vanillylmandelic Acid (ng/mg-Cr)              | 0.45 ± 0.13                    | 0.41 ± 0.12                    | -0.05 [-0.08, -0.02]        | 0.79 [0.57, 0.91] |
| Kynurenic Acid (ng/mg-Cr)                     | 0.26 ± 0.08                    | 0.25 ± 0.08                    | -0.01 [-0.02, -0.00]        | 0.95 [0.88, 0.98] |
| Xanthurenic Acid (ng/mg-Cr)                   | 0.06 (0.05, 0.08)              | 0.06 (0.05, 0.07)              | -0.00 [-0.00, 0.00]         | 0.98 [0.95, 0.99] |
| 5-HIAA (ng/mg-Cr)                             | 0.46 (0.43, 0.57)              | 0.44 (0.40, 0.55)              | -0.01 [-0.05, 0.02]         | 0.98 [0.96, 0.99] |
| Pyroglutamic Acid (ng/mg-Cr)                  | 4.42 ± 0.72                    | 4.06 ± 0.69                    | -0.41 [-0.58, -0.23]        | 0.75 [0.51, 0.89] |
| β-Hydroxyisovaleric Acid (ng/mg-Cr)           | 0.29 ± 0.12                    | 0.27 ± 0.12                    | -0.02 [-0.03, -0.00]        | 0.95 [0.88, 0.98] |

For liquid and dried measurements, data presented as mean±SD for normally distributed variables and median (IQR) for skewed variables; the differences were normally distributed and are presented as mean [95% CI].

ap<0.05; bp<0.0001 for the liquid minus dried difference by paired t-test

5-HIAA = 5-hydroxyindoleacetic acid, Cr = creatinine, DHEA = dehydroepiandrosterone, ICC = intraclass correlation coefficient

Agreement between the DUTCH 4-spot and 24-hour urine collection for hormonal measures

The measurement of reproductive hormones in urine samples collected four times throughout the day were comparable to the gold standard of a 24-h urine collection (Table 5). As the measures from the 4-
spot urine collection are reported in ng/mg-Cr and the 24-h urine measures are reported in ug/d, sex-specific Z-scores were created for direct comparison of the two methodologies. There was excellent consistency (ICC > 0.9) for the majority of the analytes and good consistency for the remainder (estriol, 5a and 5b-androstanediol) (Table 5). There was no systematic directionality to the differences between any of the Z-scores (Table 5). Representative interclass (Spearman) correlations between the analytes are shown in Fig. 3 (the remainder are shown in Supplementary Fig. 3).

A sensitivity analysis to verify the need for creatinine correction was done by calculating ICCs for the agreement between sex-specific Z-scores from the 24-h measures and the 4-spot assay without correction for creatinine. Without the creatinine correction, the ICCs were all lower than those observed with the creatinine correction (with the exception of estriol which had a slightly higher ICC by 0.04) with the degree of difference ranging from −0.04 to 0.15 and averaging 0.07. An example of the interclass correlations (Spearman) between the 24-h measures and the 4-spot assay with and without the creatinine corrections is shown in Supplementary Fig. 4.
Table 5
Comparison of the urinary hormone profile using the 4-spot (DUTCH) or 24-h urine collection method (n = 26).

| Variable               | 24-h urine collection (µg/d) | 4-spot (ng/mg-Cr) | Z-score difference [95% CI] | ICC [95% CI] |
|------------------------|-----------------------------|-------------------|----------------------------|--------------|
| Estrone                | 13.69 (6.32, 19.16)         | 14.37 (7.13, 18.75) | 0.00 [-0.13, 0.13]          | 0.95 [0.89, 0.97] |
| Estradiol              | 1.73 (0.80, 3.26)           | 1.68 (0.92, 3.81)  | 0.00 [-0.16, 0.16]          | 0.92 [0.83, 0.96] |
| Estriol                | 6.82 (3.57, 12.80)          | 7.39 (4.15, 12.96) | 0.00 [-0.24, 0.24]          | 0.82 [0.64, 0.91] |
| 2-hydroxyestrone       | 3.33 (1.27, 6.24)           | 3.72 (1.45, 6.75)  | -0.00 [-0.09, 0.09]         | 0.97 [0.94, 0.99] |
| 2-hydroxyestradiol     | 0.25 (0.11, 0.67)           | 0.30 (0.13, 0.49)  | -0.00 [-0.10, 0.10]         | 0.97 [0.93, 0.99] |
| 4-hydroxyestrone       | 0.37 (0.19, 0.75)           | 0.45 (0.27, 0.81)  | -0.00 [-0.15, 0.15]         | 0.93 [0.86, 0.97] |
| 16-hydroxyestrone      | 0.89 (0.42, 1.48)           | 0.93 (0.57, 1.69)  | 0.00 [-0.19, 0.19]          | 0.90 [0.77, 0.95] |
| 2-methoxyestrone       | 2.27 (1.30, 3.80)           | 2.11 (1.54, 4.15)  | 0.00 [-0.19, 0.19]          | 0.90 [0.78, 0.95] |
| Testosterone           | 9.15 (4.97, 51.92)          | 9.33 (5.36, 54.73) | -0.00 [-0.10, 0.10]         | 0.97 [0.93, 0.98] |
| Epitestosterone        | 7.23 (4.01, 11.23)          | 7.53 (3.81, 13.90) | -0.00 [-0.07, 0.07]         | 0.99 [0.97, 0.99] |
| 5a-Dihydrotestosterone | 5.53 (2.72, 11.59)          | 6.40 (2.16, 11.91) | -0.00 [-0.09, 0.09]         | 0.97 [0.94, 0.99] |
| Androsterone           | 1331.99 (854.41, 1940.29)   | 1346.46 (818.59, 2065.66) | -0.00 [-0.09, 0.09]         | 0.97 [0.94, 0.99] |
| Etiocholanolone        | 811.74 (463.17, 1045.23)    | 797.60 (475.43, 1061.66) | -0.00 [-0.09, 0.09]         | 0.98 [0.95, 0.99] |
| 5a-Androstanediol      | 102.50 (54.83, 197.14)      | 86.74 (51.31, 200.70) | -0.00 [-0.27, 0.27]         | 0.78 [0.57, 0.89] |
| 5b-Androstanediol      | 35.58 (14.05, 60.75)        | 34.49 (13.91, 62.77) | 0.00 [-0.22, 0.22]          | 0.85 [0.70, 0.93] |
| DHEA                   | 166.14 (80.45, 431.61)      | 162.85 (78.17, 394.62) | -0.00 [-0.05, 0.05]         | 0.99 [0.99, 1.00] |

The ICCs were calculated between measurements expressed as standardized sex-specific Z-scores (mean ± SD for all = 0.00 ± 0.98). Data are presented as median (IQR) for measurements and the difference (24-h minus 4-spot) in individual Z-scores is presented as mean [95% confidence interval].
Discussion

This study demonstrated the feasibility of accurately measuring multiple (up to 32) analytes in dried urine samples collected on filter paper using assays that conform to CLIA criteria. All measurements from dried urine demonstrated at least good agreement with measures from liquid urine, and the majority (83%) demonstrated excellent agreement with intraclass correlations greater than 0.9. For most analytes, neither loss nor excess concentration occurred during the sample drying or laboratory extraction process. In addition, measurement of the reproductive steroid hormones, which are usually evaluated from a 24-hr collection due to their pulsatile release\textsuperscript{58}, were well represented by the 4-spot dried urine collection with at least good agreement of the 4-spot measurement with the 24-h gold standard measure for all steroid metabolites and excellent agreement (> 0.9) for the majority (82%). There were no systematic differences between the relative amount of hormone collected by either methodology. The 4-spot dried urine (DUTCH) methodology allows for efficient, accurate assessment of numerous urine metabolites using a convenient collection method, while avoiding the need for a full 24-hr liquid urine collection.

The 4-spot dried urine collection has previously been shown to be representative of select 24-h measures of steroidal hormones by our group\textsuperscript{12}, as measurement of urinary a-pregnanediol, b-pregnanediol, estrone, and estradiol with this method are representative of both 24-h urine collections as well as serum hormone concentrations. In fact, repeated assessments over a month demonstrated that the dried urine collections could accurately recreate the changes observed in serum during the menstrual cycle\textsuperscript{12}. In addition, not only does the 4-spot urine method accurately represent a 24-h urine collection for urinary cortisol, cortisone, and cortisol metabolites, but it can also be used to represent the expected diurnal pattern observed with salivary measures, if each of the four collections is considered individually\textsuperscript{15}.

Previous studies have validated the usefulness of high throughput GC-MS/MS for urine steroid profiling of more than 30 metabolites; however, this was done in liquid urine\textsuperscript{5}. Conversely, measurement of organic acids in spot dried urine samples using filter paper has already been well-validated as a technique for screening neonates for metabolic disorders\textsuperscript{16,59,60} and for screening for neuroblastoma\textsuperscript{61} with similar recoveries obtained from liquid and dried urine. Dried urine has also been used to measure other urine analytes of interest, such as sodium and potassium, with similarly high levels of stability\textsuperscript{62}. As with others who used either filter paper or cotton swabs\textsuperscript{63}, we found that dried urine results are in agreement with liquid urine results, reduced the burden on patients, and had good stability over time\textsuperscript{12}. Still, agreement between 24-h urine collections and early-morning, single spot urine collections for hormonal analysis are often poor\textsuperscript{64}. This study now extends our prior findings\textsuperscript{12,15} to show that the increase to four spot urines spaced throughout the waking hours provides better coverage of the hormonal output for all

\textsuperscript{a}all p-values > 0.9 by paired t-test

Cr = creatinine, DHEA = dehydroepiandrosterone, ICC = intraclass correlation coefficient
the male and female reproductive hormones and metabolites, resulting in strong agreement with 24-h urine measures.

There are some caveats that must be considered when interpreting our results. During the urine collection, there may have been differences in saturation of the filter paper. Expressing the analyte concentration per mg of creatinine is designed to address this, while also correcting for hydration. The method used for creatinine adjustment also accounts for differences in creatinine excretion related to body size. This does rely on accurate self-reporting of age, height, and weight by the participants, so an estimate of expected creatinine excretion can be made. This may lead to the introduction of inaccuracies due to misreporting of individual characteristics; however, our statistical sensitivity analyses indicated that the DUTCH measurements were in better agreement with the 24-h urine results with the application of the creatinine corrections (see Supplementary Fig. 4), with the ICC for some metabolites increasing by as much as 0.15 and raising the level of agreement with 24-h measures from good to excellent.

One of the limitations of this 4-spot dried urine method is that reference ranges are laboratory-specific and non-standardized. Still, interpretation of values above and below these reference ranges should be similar to that of other assays. In this study, there was some loss of hormone for estrone and estriol with the filter paper methodology, which may be related to differences in extraction efficiency between the steroid conjugates and creatinine, loss during the drying process, or incomplete saturation of the filter paper. Still, the difference was less than 12% of the total and would be compensated for by an adjustment of the reference range. In addition, we have previously shown that the dried urine measure of estrone has clinical utility because it is representative of serum estrogen measurements12. A number of organic acids plus DHT were more concentrated in the dried urine samples, on average. This may be due to differences in extraction efficiency, a matrix effect or analyte concentration during the drying process; however, this difference did represent less than 10% of the sample. Fortunately, due to the high level of agreement between the Z-scores from the DUTCH methodology and 24-h collections, laboratory reference ranges should account for these differences. Another issue is there are known genetic differences in glucuronidation of testosterone that may impact relative metabolism and urinary concentrations of testosterone and epitestosterone65, and this may mean urinary androgen measures are not fully representative of production rates in a small percentage of individuals. There are also genetic differences in the enzymes that metabolize estrogens, potentially shifting the ratio of 2-hydroxylation to 16-hydroxylation metabolites66, but these differences may be clinically relevant and indicative of cancer risk67.

The methodology of a 4-spot urine collection on filter paper followed by GC-MS/MS or LC-MS/MS offers some advantages. The collection of dried urine on filter paper results in stable measurement of steroid hormones for extended periods of time both by us12 and others13 for up to one year14, even at ambient temperature. Concentrations of organic acids are also stable on dried filter paper for weeks68,69. Mass spectrometry assays, which are now the gold standard for measurement of steroid hormones in blood and urine11, allow for the use of small sample volumes with excellent sensitivity and accuracy along with
simultaneous measurement of a relatively large number of analytes. In combination with chromatography, either gas or liquid, it provides precise separation of closely related molecules\textsuperscript{70} by their chemical and physical properties. GC-MS/MS does not exclude any lipophilic steroids, and so a run will contain all excreted steroids\textsuperscript{9}. The use of the \textit{H. pomatia} enzymes adds to the accuracy of the quantification of the hormone conjugates, as these enzymes include both a sulfatase and a glucuronidase. The method of GC-MS/MS does require an additional extraction and derivatization step, but workflows can be optimized to maximize throughput. A 24-h urine collection may be difficult for some patients to fully collect, especially if they are not able to remain at home for an entire day, are disabled, or are incontinent. This methodology removes that barrier and provides the ability to measure multiple hormones at once with a noninvasive collection method, obtaining a complete picture of both production and clearance of the major steroidal hormones.

A multitude of uses, both in research and in clinical scenarios, could be envisioned for assays that are able to measure multiple steroid hormones and organic acids in conveniently collected urine samples on filter paper. For example, the full range of hormonal changes in individuals related to disruption of the natural sleep cycle could be evaluated simultaneously. It is already known that the peak 6-sulfatoxymelatonin, as representative of melatonin, is lower in people working the night shift\textsuperscript{71}; a full appreciation of the urinary steroid profile in individuals who work at night could add to this prior research. Similarly, urine profiling may help to fully define the changes expected in genetic syndromes of steroidogenesis\textsuperscript{5,72} and errors of metabolism\textsuperscript{17}. Dried urine samples may be of particular benefit in screening neonates for organic acid disorders\textsuperscript{16,17}, and there is recent interest in a possible association of organic acids with neuropsychiatric disorders\textsuperscript{73–75}. The ability to look at a full urine profile can provide a more integrated view of the patient; for example, patients using oral contraceptives often have higher xanthurenic acid with concurrent pyroxidine deficiency\textsuperscript{76}, both of which would be observable using dried urine analysis. A greater understanding of the full effect of changes in hormonal concentrations and metabolites or important clinical subgroups could be determined for both exogenous use of hormones and for exposure to endocrine disrupting compounds like bisphenol A\textsuperscript{77,78}. Urine hormone profiling might also be used to fully describe age related changes, i.e. through puberty or menopause.

**Conclusions**

Mass spectrometry allows for the assessment of a full hormone profile in a small volume of urine such that an expanded view of both hormone production and clearance can be observed. In addition, results from dried urine are in strong agreement with those obtained from liquid urine. In combination with four spot urine collections on filter paper collected throughout the waking hours, we have shown that it is possible to accurately represent a 24-h urine collection. This technology may be useful to the clinician wishing to perform a large series of tests on patients to narrow the differential diagnosis, for those monitoring hormonal therapy or evaluating the menstrual cycle, or for those who need to reduce the burden of collection for their patients. This four-spot, dried urine method allows for assessment of both
diurnal patterns\textsuperscript{15} as well as total daily production, allowing for a comprehensive evaluation of adrenal and reproductive hormones and other urine metabolites.

**Abbreviations**

2OHE1
2-hydroxyestrone
2-methoxyE1
2-methoxyestrone
4OHE1
4-hydroxyestrone
5-HIAA
5-hydroxyindoleacetic acid
16OHE1
16-hydroxyestrone
CAN
acetonitrile
CLIA
Clinical Laboratory Improvement Amendments
Cr
creatine
DHEA
dehydroepiandrosterone
DHT
5α-dihydrotestosterone
DUTCH
Dried Urine Testing for Comprehensive Hormones
E1
estrone
E2
estradiol
E3
estriol
EpiT
epitestosterone
GC-MS/MS
gas chromatography with tandem mass spectrometry
Hiv
β-hydroxyisovaleric
HVA
Declarations

Ethics approval and consent to participate

The research was conducted on healthy adult volunteers at a commercial testing laboratory. Informed consent was obtained from all participants prior to the study or the IRB determined that written informed consent could be waived for the study population. All methods were performed in accordance with the relevant guidelines and regulations required by both the National University of Natural Medicine Institutional Review Board and CLIA.

Availability of data and material

The datasets acquired and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable

Competing interests

Precision Analytical, Inc. is a commercial laboratory offering hormone testing to medical practitioners and individuals. All statistics were calculated and interpreted by an independent agent.

Funding

Precision Analytical Laboratory, Inc. provided funds to run urine and serum assays.
Author's contributions

MN developed the methodology of the dried urine assay, designed the studies, interpreted the data, and made substantial contributions to the manuscript. DC acquired and interpreted the data and contributed to the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge Danielle Martinot for writing the IRB proposal for this study and Marie Thearle, MD for creating tables and figures and assistance with statistical analysis and interpretation of the data. And thanks to the volunteers who provided samples for analysis.

Author's information

MN, DC: Precision Analytical, Inc. 3138 NE Rivergate Street #301C, McMinnville, OR 97128 USA

References

1. Sansone A, Sansone M, Selleri R, et al. Monitoring testosterone replacement therapy with transdermal gel: when and how? Journal of Endocrinological Investigation. 2019;42(12):1491–1496. doi:10.1007/s40618-019-01082-x
2. Rodgers M. Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms. British Journal of General Practice. 1997;47(416):161–165. Accessed October 11, 2020. https://pubmed.ncbi.nlm.nih.gov/9167320/
3. de Medeiros, Sebastião Freitas, Barbosa, Jacklyne Silva, Yamamoto MMW. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res. 2015;41(2):254–263. doi:10.1111/jog.12524
4. Ketha H, Kaur S, Grebe SK, Singh RJ. Clinical applications of LC-MS sex steroid assays: Evolution of methodologies in the 21st century. Current Opinion in Endocrinology, Diabetes and Obesity. 2014;21(3):217–226. doi:10.1097/MED.0000000000000068
5. Jong WHAD, Buitenwerf E, Pranger AT, et al. Determination of reference intervals for urinary steroid profiling using a newly validated GC-MS/MS method. Clinical Chemistry and Laboratory Medicine. 2017;56(1):103–112. doi:10.1515/cclm-2016-1072
6. Nicolau GY, Haus E. Chronobiology of the endocrine system. Endocrinologie. 1989;27(3):153–183.
7. Ghiraldi EM, Reddy M, Li T, Lawler AC, Friedlander JL. Factors associated with compliance in submitting 24-hour urine collections in an underserved community. Journal of Endourology. 2017;31:S64-S68. doi:10.1089/end.2016.0594
8. Sninsky BC, Nakada SY, Penniston KL. Does socioeconomic status, age, or gender influence appointment attendance and completion of 24-hour urine collections? Urology. 2015;85(3):568–573.
9. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CHL. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). *Journal of Steroid Biochemistry and Molecular Biology*. 2010;121(3–5):496–504. doi:10.1016/j.jsbmb.2010.04.010

10. Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. *Journal of Steroid Biochemistry and Molecular Biology*. 2010;121(3–5):491–495. doi:10.1016/j.jsbmb.2010.05.001

11. Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. *Journal of Steroid Biochemistry and Molecular Biology*. 2010;121(3–5):491–495. doi:10.1016/j.jsbmb.2010.05.001

12. Newman M, Pratt SM, Curran DA, Stanczyk FZ. Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC–MS/MS). *BMC Chemistry*. 2019;13(1). doi:10.1186/s13065-019-0539-1

13. Blasco H, Garrigue MA, de Vos A, et al. Filter paper saturated by urine sample in metabolic disorders detection by proton magnetic resonance spectroscopy. *Analytical and Bioanalytical Chemistry*. 2010;396(3):1205–1211. doi:10.1007/s00216-009-3280-0

14. Shideler SE, Munro CJ, Johl HK, Taylor HW, Lasley BL. Urine and fecal sample collection on filter paper for ovarian hormone evaluations. *American Journal of Primatology*. 1995;37(4):305–315. doi:10.1002/ajp.1350370405

15. Newman M, Curran DA, Mayfield BP. Dried Urine and Salivary Profiling for Complete Assessment of Cortisol and Cortisol Metabolites. *Journal of Clinical and Translational Endocrinology*. 2020. doi:10.1016/j.jcte.2020.100243

16. Fu XW, Iga M, Kimura M, Yamaguchi S. Simplified screening for organic acidemia using GC/MS and dried urine filter paper: A study on neonatal mass screening. *Early Human Development*. 2000;58(1):41–55. doi:10.1016/S0378-3782(00)00053-0

17. Matsumoto I, Kuhara T. A new chemical diagnostic method for inborn errors of metabolism by mass spectrometry - Rapid, practical, and simultaneous urinary metabolites analysis. *Mass Spectrometry Reviews*. 1996;15(1):43–57. doi:10.1002/(SICI)1098-2787(1996)15:1<43::AID-MAS3>3.0.CO;2-B

18. Savkovic S, Lim S, Jayadev V, et al. Urine and Serum Sex Steroid Profile in Testosterone-Treated Transgender and Hypogonadal and Healthy Control Men. *Journal of Clinical Endocrinology and Metabolism*. 2018;103(6):2277–2283. doi:10.1210/jc.2018-00054

19. Klein DA, Paradise SL, Reeder RM. Amenorrhea: A systematic approach to diagnosis and management. *American Family Physician*. 2019;100(1):39–48. Accessed October 12, 2020. https://pubmed.ncbi.nlm.nih.gov/31259490/

20. Collins WP, Collins PO, Kilpatrick MJ, Manning PA, Pike JM, Tyler JP. The concentrations of urinary oestrone-3-glucuronide, LH and pregnanediol-3α-glucuronide as indices of ovarian function. *Acta Endocrinologica*. 1979;90(2):336–348. doi:10.1530/acta.0.0900336
21. Bassi F, Bartolini O, Neri AS, et al. Usefulness of early morning urine estrone-3-glucuronide assay in the monitoring ovarian secretory function in precocious puberty. *Journal of Endocrinological Investigation*. 1995;18(2):98–103. doi:10.1007/BF03349708

22. Friel PN, Hinchcliffe C, Wright J v. Hormone replacement with estradiol: Conventional oral doses result in excessive exposure to estrone. *Alternative Medicine Review*. 2005;10(1):36–41. Accessed October 12, 2020. https://pubmed.ncbi.nlm.nih.gov/15771561/

23. Michels KB, Binder N, Courant F, Franke AA, Osterhues A. Urinary excretion of sex steroid hormone metabolites after consumption of cow milk: A randomized crossover intervention trial. *American Journal of Clinical Nutrition*. 2019;109(2):402–410. doi:10.1093/ajcn/nqy279

24. Mueck AO, Seeger H, Wallwiener D. Endogenous estradiol metabolism during treatment with oral contraceptives. *International Journal of Clinical Pharmacology and Therapeutics*. 2004;42(3):160–164. doi:10.5414/CPP42160

25. Mueck AO, Seeger H, Wallwiener D. Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. *Maturitas*. 2002;43(2):87–93. doi:10.1016/S0378-5122(02)00160-3

26. Kurzer MS. Hormonal effects of soy in premenopausal women and men. In: *Journal of Nutrition*. Vol 132. American Institute of Nutrition; 2002. doi:10.1093/jn/132.3.570s

27. Dhayat NA, Marti N, Kollmann Z, et al. Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites. *PLoS ONE*. 2018;13(10):1–15. doi:10.1371/journal.pone.0203903

28. Smith AJ, Phipps WR, Thomas W, Schmitz KH, Kurzer MS. The effects of aerobic exercise on estrogen metabolism in healthy premenopausal women. *Cancer Epidemiology Biomarkers and Prevention*. 2013;22(5):756–764. doi:10.1158/1055-9965.EPI-12-1325

29. Thomson CA, Chow HHS, Wertheim BC, et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. *Breast Cancer Research and Treatment*. 2017;165(1):97–107. doi:10.1007/s10549-017-4292-7

30. Takanashi K, Honma T, Kashiwagi T, Honjo H, Yoshizawa I. Detection and measurement of urinary 2-hydroxyestradiol 17-sulfate, a potential placental antioxidant during pregnancy. *Clinical Chemistry*. 2000;46(3):373–378. doi:10.1093/clinchem/46.3.373

31. Sweeney C, Liu G, Yiannoutsos C, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. *Clinical Cancer Research*. 2005;11(18):6625–6633. doi:10.1158/1078-0432.CCR-05-0440

32. Newman SP, Leese MP, Purohit A, et al. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. *International Journal of Cancer*. 2004;109(4):533–540. doi:10.1002/ijc.20045

33. Stanczyk FZ. Measurement of androgens in women. *Seminars in Reproductive Medicine*. 2006;24(2):78–85. doi:10.1055/s-2006-939566
34. Khera M. Male hormones and men’s quality of life. *Current Opinion in Urology*. 2016;26(2):152–157. doi:10.1097/MOU.0000000000000256

35. KAPELrud H, JOHANNESEN, OFTEBRO H. Testosterone/epitestosterone ratio in urine: a possible diagnostic tool in the disclosure of exogenous testosterone administration. *Journal of Internal Medicine*. 1992;232(5):453–455. doi:10.1111/j.1365-2796.1992.tb00614.x

36. Mauvais-Jarvis P, Kuttenn F, Mowszowicz I. Hirsutism. *Monographs on endocrinology*. 1981;19:1-116. Accessed October 12, 2020. https://pubmed.ncbi.nlm.nih.gov/6454061/

37. Wu C, Wei K, Jiang Z. 5α-reductase activity in women with polycystic ovary syndrome: A systematic review and meta-analysis. *Reproductive Biology and Endocrinology*. 2017;15(1):1–9. doi:10.1186/s12958-017-0242-9

38. Dennedy MC, Annamalai AK, Prankerd-Smith O, et al. Low DHEAS: A sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. *Journal of Clinical Endocrinology and Metabolism*. 2017;102(3):786–792. doi:10.1210/jc.2016-2718

39. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. *Journal of Pineal Research*. 1998;24(4):230–238. doi:10.1111/j.1600-079X.1998.tb00538.x

40. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. *Journal of the National Cancer Institute*. 2005;97(14):1084–1087. doi:10.1093/jnci/dji190

41. Klee GG. Cobalamin and folate evaluation: Measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. *Clinical Chemistry*. 2000;46(8 II):1277–1283. doi:10.1093/clinchem/46.8.1277

42. Grouzmann E, Centeno C, Eugster PJ. Quantication of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method. *Clinical Chemistry and Laboratory Medicine*. 2018;56(9):1533–1541. doi:10.1515/cclm-2017-1120

43. Sies CW, Florkowski CM, Sullivan M, Mackay R, George PM. Urinary VMA, dopamine and the likelihood of neuroblastoma: A preferred way of reporting laboratory results? *Annals of Clinical Biochemistry*. 2006;43(4):300–305. doi:10.1258/000456306777695645

44. Curto M, Lionetto L, Negro A, et al. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. *Journal of Headache and Pain*. 2016;17(1). doi:10.1186/s10194-016-0620-2

45. Curto M, Lionetto L, Negro A, et al. Altered kynurenine pathway metabolites in serum of chronic migraine patients. *Journal of Headache and Pain*. 2016;17(1). doi:10.1186/s10194-016-0638-5

46. Luhy AL, Brin M, Gordon M, Davis P, Murphy M, Spiegel H. Vitamin B 6 metabolism in users of oral contraceptive agents. I. Abnormal urinary xanthurenic acid excretion and its correction by pyridoxine. *The American journal of clinical nutrition*. 1971;24(6):684–693. doi:10.1093/ajcn/24.6.684

47. Connick JH, Stone TW. The role of kynurenines in diabetes mellitus. *Medical Hypotheses*. 1985;18(4):371–376. doi:10.1016/0306-9877(85)90104-5
48. Murakami K, Haneda M, Yoshino M. Prooxidant action of xanthurenic acid and quinoline compounds: Role of transition metals in the generation of reactive oxygen species and enhanced formation of 8-hydroxy-2′-deoxyguanosine in DNA. *BioMetals*. 2006;19(4):429–435. doi:10.1007/s10534-005-4528-6

49. Tormey WP, Fitz Gerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. *Postgraduate Medical Journal*. 1995;71(839):542–545. doi:10.1136/pgmj.71.839.542

50. Tarantino G, Savastano S, Colao A, Polichetti G, Capone D. Urinary excretion of 5-hydroxy-3-indoleacetic acid in dystimic/depressed, adult obese women: What correlations to hepatic steatosis? *International Journal of Immunopathology and Pharmacology*. 2011;24(3):769–779. doi:10.1177/039463201102400323

51. Yu YM, Ryan CM, Fei ZW, et al. Plasma L-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely burned adult humans. *American Journal of Physiology - Endocrinology and Metabolism*. 2002;282(2 45–2). doi:10.1152/ajpendo.00206.2001

52. Alhourani HM, Kumar A, George LK, Sarwar T, Wall BM. Recurrent Pyroglutamic Acidosis Related to Therapeutic Acetaminophen. *American Journal of the Medical Sciences*. 2018;355(4):387–389. doi:10.1016/j.amjms.2017.08.001

53. Horvath TD, Matthews Nl, Stratton SL, Mock DM, Boysen G. Measurement of 3-hydroxyisovaleric acid in urine from marginally biotin-deficient humans by UPLC-MS/MS. In: *Analytical and Bioanalytical Chemistry*. Vol 401. Anal Bioanal Chem; 2011:2805–2810. doi:10.1007/s00216-011-5356-x

54. Sealey WM, Teague AM, Stratton SL, Mock DM. Smoking accelerates biotin catabolism in women. *American Journal of Clinical Nutrition*. 2004;80(4):932–935. doi:10.1093/ajcn/80.4.932

55. Kawasaki T, Uezono K, Itoh K, Ueno M. Prediction of 24-hour urinary creatinine excretion from age, body weight and height of an individual and its application. [*Nippon kōshū eisei zasshi*] *Japanese journal of public health*. 1991;38(8):567–574. Accessed July 5, 2020. https://europepmc.org/article/med/1747547

56. Bujang MA, Baharum N. A simplified guide to determination of sample size requirements for estimating the value of intraclass correlation coefficient: A review. *Archives of Orofacial Sciences*. 2017;12(1):1–11.

57. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. *Biometrics*. 1977;33(1):159. doi:10.2307/2529310

58. Keenan DM, Veldhuis JD. Pulsatility of hypothalamo-pituitary hormones: A challenge in quantification. *Physiology*. 2016;31(1):34–50. doi:10.1152/physiol.00027.2015

59. Fu X, Kimura M, Iga M, Yamaguchi S. Gas chromatographic-mass spectrometric screening for organic acidemias using dried urine filter paper: Determination of α-ketoacids. *Journal of Chromatography B: Biomedical Sciences and Applications*. 2001;758(1):87–94. doi:10.1016/S0378-4347(01)00101-3
60. Tuchman M, McCann MT, Johnson PE, Lemieux B. Screening newborns for multiple organic acidurias in dried filter paper urine samples: Method development. *Pediatric Research*. 1991;30(4):315–321. doi:10.1203/00006450-199110000-00005

61. Seviour JA, McGill AC, Craft AW, et al. Screening for neuroblastoma in the northern region of England laboratory aspects. *Journal of Pediatric Hematology/Oncology*. 1992;14(4):332–336. doi:10.1097/00043426-199211000-00009

62. Tarik M, Ramakrishnan L, Amarchand R, et al. Feasibility of measuring sodium, potassium and creatinine from urine sample on dried filter paper. *Bioanalysis*. 2019;11(8):689–701. doi:10.4155/bio-2018-0295

63. Monošík R, Dragsted LO. Dried urine swabs as a tool for monitoring metabolite excretion. *Bioanalysis*. 2018;10(17):1371–1381. doi:10.4155/bio-2018-0042

64. Bileck A, Frei S, Vogt B, Groessl M. Urinary steroid profiles: comparison of spot and 24-hour collections. *Journal of Steroid Biochemistry and Molecular Biology*. 2020;200. doi:10.1016/j.jsbmb.2020.105662

65. Sten T, Bichlmaier I, Kuuranne T, Leinonen A, Yli-Kauhaluoma J, Finel M. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. *Drug Metabolism and Disposition*. 2009;37(2):417–423. doi:10.1124/dmd.108.024844

66. Yong M, Schwartz SM, Atkinson C, et al. Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States. *Journal of Steroid Biochemistry and Molecular Biology*. 2011;124(1–2):10–18. doi:10.1016/j.jsbmb.2010.12.014

67. Sampson JN, Falk RT, Schairer C, et al. Association of estrogen metabolism with breast cancer risk in different cohorts of postmenopausal women. *Cancer Research*. 2017;77(4):918–925. doi:10.1158/0008-5472.CAN-16-1717

68. Shinka T, Ohse M, Inoue Y, Kuhara T. Stability of 5-aminolevulinic acid on dried urine filter paper for a diagnostic marker of tyrosinemia type I. In: *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*. Vol 823. J Chromatogr B Analty Technol Biomed Life Sci; 2005:44–46. doi:10.1016/j.jchromb.2005.02.002

69. McCann M, Thompson M, Gueron IC, Lemieux B, Giguere R, Tuchman M. Methylmalonic acid quantification by stable isotope dilution gas chromatography-mass spectrometry from filter paper urine samples. *Clin Chem*. 1996;42(6 Pt 1):910–914.

70. Homer N, Kothiya S, Rutter A, Walker BR, Andrew R. Gas chromatography tandem mass spectrometry offers advantages for urinary steroids analysis. *Analytical Biochemistry*. 2017;538:34–37. doi:10.1016/j.ab.2017.09.002

71. Davis S, Mirick DK, Chen C, Stanczyk FZ. Night shift work and hormone levels in women. *Cancer Epidemiology Biomarkers and Prevention*. 2012;21(4):609–618. doi:10.1158/1055-9965.EPI-11-1128
72. Pussard E, Travers S, Bouvattier C, et al. Urinary steroidomic profiles by LC-MS/MS to monitor classic 21-Hydroxylase deficiency. *Journal of Steroid Biochemistry and Molecular Biology*. 2020;198. doi:10.1016/j.jsbmb.2019.105553

73. Marc DT, Ailts JW, Campeau DCA, Bull MJ, Olson KL. Neurotransmitters excreted in the urine as biomarkers of nervous system activity: Validity and clinical applicability. *Neuroscience and Biobehavioral Reviews*. 2011;35(3):635–644. doi:10.1016/j.neubiorev.2010.07.007

74. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BWJH. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. *Psychoneuroendocrinology*. 2015;51:164–175. doi:10.1016/j.psyneuen.2014.09.025

75. Abou-Saleh MT, Coppen A. Psychiatric progress. The biology of folate in depression: Implications for nutritional hypotheses of the psychoses. *Journal of Psychiatric Research*. 1986;20(2):91–101. doi:10.1016/0022-3956(86)90009-9

76. Deac OM, Mills JL, Shane B, et al. Tryptophan catabolism and vitamin B-6 status are affected by gender and lifestyle factors in healthy young adults. *Journal of Nutrition*. 2015;145(4):701–707. doi:10.3945/jn.114.203091

77. Kim EJ, Lee D, Chung BC, Pyo H, Lee J. Association between urinary levels of bisphenol-A and estrogen metabolism in Korean adults. *Science of the Total Environment*. 2014;470–471:1401–1407. doi:10.1016/j.scitotenv.2013.07.040

78. Bloem LM, Storbeck KH, Swart P, du Toit T, Schloms L, Swart AC. Advances in the analytical methodologies: Profiling steroids in familiar pathways-challenging dogmas. *Journal of Steroid Biochemistry and Molecular Biology*. 2015;153:80–92. doi:10.1016/j.jsbmb.2015.04.009